Optimization of amino acid-stabilized erythropoietin parenteral formulation: In vitro and in vivo assessment

Fayed, Bahgat E.; Tawfik, Abdulkader F.; Yassin, Alaa Eldeen B.

doi:10.1515/acph-2016-0007

Abstract

The aim of this study was to optimize the formulation of erythropoietin (EPO) using amino acids instead of human serum albumin (HSA) and to evaluate its in vivo stability in order to avoid the risk of viral contamination and antigenicity. Different EPO formulations were developed in such a way as to allow studying the effects of amino acids and surfactants on the EPO stability profile. The main techniques applied for EPO analysis were ELISA, Bradford method, and SDS gel electrophoresis. The in vivo stability was evaluated in a Balb-c mouse animal model. The results showed that the presence of surfactant was very useful in preventing the initial adsorption of EPO on the walls of vials and in minimizing protein aggregation. Amino acid combinations, glycine with glutamic acid, provided maximum stability. Formulation F4 (containing glycine, glutamic acid and Tween 20) showed minimum aggregation and degradation and in vivo activity equivalent to commercially available HSA-stabilized EPO (Eprex^®).

References

1. S. Elliott, E. Pham and I. C. Macdougall, Erythropoietins: A common mechanism of action, Exp. Hematol.36 (2008) 1573–1584; DOI: 10.1016/j.exphem.2008.08.003.10.1016/j.exphem.2008.08.003
Search in Google Scholar
2. A. Sytkowski, L. Feldma and D. Zurbuch, Biological ability and structural stability of N-deglycosylated recombinant erythropoietin, Biochem. Biophys. Res. Commun.176 (1991) 698–704; DOI: 10.1016/S0006-291X(05)80240-2.10.1016/S0006-291X(05)80240-2
Search in Google Scholar
3. S. T. Koury, M. C. Bondurant and M. J. Koury, Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization, Blood71 (1988) 524–527; DOI: 10.1038/ki.1993.115.10.1038/ki.1993.115
Search in Google Scholar
4. A. J. Erslev, Erythropoietin titers in health and disease, Semin. Hematol.28 (Suppl 3) (1991) 2–8.
Search in Google Scholar
5. C. Lacombe, J. L. Da Silva, P. Bruneval, J. G. Fournier, F. Wendling, N. Casadevall, J. P. Camilleri, J. Bariety, B. Varet and P. Tambourin, Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney, J. Clin. Invest.81 (1988) 620–623; DOI: 10.1172/JCI113363.10.1172/JCI113363
Search in Google Scholar
6. B. William, A. James and D. Pratt, Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease, Clin. Ther.29 (2007) 1368–1380; DOI: 10.1016/j.clinthera.2007.07.014.10.1016/j.clinthera.2007.07.014
Search in Google Scholar
7. S. Sifakis, E. Angelakis, E. Vardaki, Y. Koumantaki, I. Matalliotakis and E. Koumantakis, Erythropoietin in the treatment of iron deficiency anemia during pregnancy, Gynecol. Obstet. Invest. 51 (2001) 150–156; DOI: 10.1159/000052914.10.1159/000052914
Search in Google Scholar
8. P. Sabbatini, Strategies for optimizing hemoglobin response in cancer patients: focus on new epoetin alfa dosing regimens, EJC Suppl.2 (2004) 36–40; DOI: 10.1016/S1359–6349(03)00106-X10.1016/S1359-6349(03)00106-X
Search in Google Scholar
9. N. V. Sipsas, S. I. Kokori, J. P. A. Ioannidis, D. Kyriaki, A. G. Tzioufas and T. Kordossis, Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type 1-related anemia, J. Infect. Des.180 (1999) 2044–2047; DOI: 10.1086/315156.10.1086/315156
Search in Google Scholar
10. J. F. Konings, J. M. Noppe, M. Mesnes and L. Jean, Improved cyclodextrin based erythropoietin formulation, WO Patent 1991011200 A1, Aug 8, 1991; ref. Chem. Abstr.139 (2003) 2074820 C.
Search in Google Scholar
11. K. C. Kwon, S. Y. Choi, Y. C. Kang, H. S. Jeh, S. J. Lee, M. J. Kim, J. E. Kim and J. S. Oh, Stable aqueous solution human erythropoietin not containing serum albumin, WO Patent 108152, December 16, 2004; ref. Chem. Abstr.141 (2004) 2528988 A1.
Search in Google Scholar
12. H. Woog, W. Gruber, H. J. Markl and F. Demmer, Stabilized erythropoietin preparations, U.S. Patent. 4992419, Feb 12, 1991; ref. Chem. Abstr.120 (1994) 1330301 C.
Search in Google Scholar
13. T. Kawaguchi and N. Shimoda, Stable erythropoietin preparation and process for formulating the same, U. S. Patent 4,806,524, Feb 21, 1989; ref. Chem. Abstr.111 (1989) 1258629 A1.
Search in Google Scholar
14. T. Kawaguchi and N. Shimoda, Method and composition for preventing the adsorption of a medicine, U. S. Patent 4,879,272, Nov 7, 1989; ref. Chem. Abstr.111 (1989) 1258628 A1.
Search in Google Scholar
15. F. J. Konings, M. J. Noppe and J. L. Mesens, Cyclodextrin based erythropoietin formulation, U.S. Patent 5,376,632, December 27, 1994; ref. Chem. Abstr.114 (1991) 2074820 A1.
Search in Google Scholar
16. T. W. Strickland, Stable and preserved erythropoietin compositions, U.S. Patent 5,661,125, August 26, 1997.
Search in Google Scholar
17. T. Yamazaki, T. Morita and H. Nagai, Erythropoietin solution preparation, U.S. Patent 6,277,367, August 21, 2001.
Search in Google Scholar
18. M. M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein – dye binding, Anal. Biochem.72 (1976) 248–254; DOI: 10.1016/0003-2697(76)90527-3.10.1016/0003-2697(76)90527-3
Search in Google Scholar
19. T. Marshall, Sodium dodecyl sulfate polyacrylamide gel electrophoresis of serum after protein denaturation in the presence or absence of 2-mercaptoethanol, Clin. Chem.30 (1984) 475–479.10.1093/clinchem/30.3.475
Search in Google Scholar
20. European Pharmacopeia, 5th ed., Strasbourg 2005, pp. 3494–3498.10.2175/193864705783865965
Search in Google Scholar
21. J. O. Hess and C. Schumann, Erythropoietin liquid formulation, U. S. Patent 7,767,644, August 3, 2010; ref. Chem. Abstr.157 (2012) 2558985 C.
Search in Google Scholar
22. T. W. Randolph and L. S. Jones, Surfactant-protein interactions, Pharm. Biotechnol.13 (2002) 159–175.10.1007/978-1-4615-0557-0_7
Search in Google Scholar
23. J. Chen and E. Dickinson, Protein/surfactant interfacial interactions Part 3. Competitive adsorption of protein + surfactant in emulsions, Colloid Surface A101 (1995) 77–85; DOI: 10.1016/0927-7757(95)03206-S.10.1016/0927-7757(95)03206-S
Search in Google Scholar
24. C. B. Youan, A. Hussain and N. T. Nguyen, Evaluation of sucrose esters as alternative surfactants in microencapsulation of proteins by the solvent evaporation method, AAPS PharmSci.5 (2003); DOI: 10.1208/ps050222.10.1208/ps050222275152912866947
Search in Google Scholar
25. E. Mori and B. Jirgensons, Effect of long-chain alkyl sulfate binding on circular dichroism and conformation of soybean trypsin inhibitor, Biochemistry20 (1981) 1630–1634; DOI: 10.1021/bi00509a034.10.1021/bi00509a0346784755
Search in Google Scholar
26. W. K. Cheung, J. Natarajan, M. Sanders, E. Vercammen, S. Begum and B. Shamara, Pharmaceutical composition of erythropoietin, U. S. Patent 248,797, December 9, 2004; ref. Chem. Abstr.133 (2000) 2369444 A1.
Search in Google Scholar
27. K. Kwon, S. Choi, Y. Kang, H. Jeh, S. Lee, M. Kim, J. Kim and J-S. Oh, Stable aqueous solution of human erythropoietin, not containing serum albumin, U. S. Patent 293419, December 20, 2007; ref. Chem. Abstr.141 (2004) 2528988 A1.
Search in Google Scholar

Optimization of amino acid-stabilized erythropoietin parenteral formulation: In vitro and in vivo assessment

Abstract

Paradigm

My account